Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration

18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...

Read more →

Reimbursement from pharmaceutical companies decreases by 288 million

11 December 2020 - The rebate from side agreements between regions and pharmaceutical companies is estimated according to the forecast ...

Read more →

TLV wants to go further with combination treatments in the field of cancer

7 December 2020 - Part of the solution for more patients to have access to combination treatments may be to create ...

Read more →

New report on TLV's medical technology assignment

3 December 2020 - In a new report, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reports on the work that ...

Read more →

Health economic assessment of Beovu in wet age-related macular degeneration

4 December 2020 - TLV has produced a health economic assessment for the regions for Beovu (brolucizumab). ...

Read more →

Takhzyro is not included in the high-cost protection

26 November 2020 - Takhzyro (lanadelumab) is a subcutaneous injection intended for routine prevention of recurrent hereditary seizures, angioedema in patients ...

Read more →

Rinvoq continues to be part of the high-cost protection with limited subsidy after reconsideration

25 November 2020 - TLV has reconsidered the subsidy for Rinvoq (upadacitinib monohydrate) and decided that the drug should continue to ...

Read more →

Additional analysis of Kyprolis in the treatment of multiple myeloma

6 November 2020 - TLV has performed an additional analysis of Kyprolis (carfilzomib) when used in combination with lenalidomide and dexamethasone ...

Read more →

The regions have applied for a price change for Cimzia and Simponi

29 October 2020 - The regions have submitted an application for a price change for Cimzia (certolizumab pegol) and Simponi (golimumab).  ...

Read more →

TLV reconsiders the subsidy of Cosentyx

28 October 2020 - TLV starts a reconsideration to investigate the current subsidy status for Cosentyx.  ...

Read more →

TLV is reconsidering the subsidy for hepatitis C drugs with side agreements

23 October 2020 - The current side agreements for hepatitis C drugs signed by the companies and the regions expire in ...

Read more →

New cancer treatment with the precision drug Vitrakvi is included in the high-cost protection

23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against ...

Read more →

TLV reconsiders the subsidy of Rinvoq

23 October 2020 - TLV starts a reconsideration of the current subsidy status for Rinvoq.  ...

Read more →

Ambrisentan, diazepam and dexamethasone new exchange groups

9 October 2020 - From November, ambrisentan 5 mg & 10 mg tablets, diazepam,10 mg tablets and dexamethasone 1 mg/mL ...

Read more →

Saxenda is not included in the high-cost protection

29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...

Read more →